Gene · 53353
Papers2,235
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,235
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer. | Biomolecules | 2023 | 37627272 | PubTator, text mining | PubMed |
| Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential. | Mol Oncol | 2023 | 37622176 | PubTator, text mining | PubMed |
| CCDC43 as a potential therapeutic target of Tian Yang Wan for the treatment of hepatocellular carcinoma by activating the hippo pathway. | Front Oncol | 2023 | 37614502 | PubTator, text mining | PubMed |
| Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy. | Am J Hematol | 2023 | 37605345 | PubTator, text mining | PubMed |
| Prevalence of antecedent Kawasaki disease in young adults with suspected acute coronary syndrome in high incidence cohort. | Front Cardiovasc Med | 2023 | 37600029 | PubTator, text mining | PubMed |
| Identification of lysosomal genes associated with prognosis in lung adenocarcinoma. | Transl Lung Cancer Res | 2023 | 37577321 | PubTator, text mining | PubMed |
| The hypoxia-associated genes in immune infiltration and treatment options of lung adenocarcinoma. | PeerJ | 2023 | 37576511 | PubTator, text mining | PubMed |
| Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. | Int J Mol Sci | 2023 | 37569598 | PubTator, text mining | PubMed |
| Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China. | NPJ Precis Oncol | 2023 | 37567953 | PubTator, text mining | PubMed |
| Suppression of tumorigenesis in LUAD by LRP1B through regulation of the IL-6-JAK-STAT3 pathway. | Am J Cancer Res | 2023 | 37560001 | PubTator, text mining | PubMed |
Secondary leiomyosarcoma of the nasal cavity in a treated patient with possible hereditary retinoblastoma with germline reciprocal translocation of RB1 and DMXL1 and somatic TP53 mutation: A case report. | Mol Clin Oncol | 2023 | 37559881 | PubTator, text mining | PubMed |
| Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers. | NPJ Precis Oncol | 2023 | 37558751 | PubTator, text mining | PubMed |
| Focused ultrasound mitigates pathology and improves spatial memory in Alzheimer's mice and patients. | Theranostics | 2023 | 37554284 | PubTator, text mining | PubMed |
| Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma. | BMC Med Genomics | 2023 | 37553698 | PubTator, text mining | PubMed |
| Mutational landscape of cancer-driver genes across human cancers. | Sci Rep | 2023 | 37550388 | PubTator, text mining | PubMed |
| Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas. | Front Oncol | 2023 | 37546405 | PubTator, text mining | PubMed |
| Molecular characterization of colorectal adenoma and colorectal cancer via integrated genomic transcriptomic analysis. | Front Oncol | 2023 | 37546388 | PubTator, text mining | PubMed |
| TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC. | Front Biosci (Landmark Ed) | 2023 | 37525904 | PubTator, text mining | PubMed |
| Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3. | J Cell Mol Med | 2023 | 37525498 | PubTator, text mining | PubMed |
| Necroptosis-related signatures identify two distinct hepatocellular carcinoma subtypes: Implications for predicting drug sensitivity and prognosis. | Heliyon | 2023 | 37519654 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53353/papers?page=16